Faron Pharmaceuticals Limited (AIM:FARN), the clinical-stage immunotherapy company, has terminated its liquidity provision agreement with Lago Kapital Oy, with effect from 5 June. The Finnish company said it considers its share liquidity sufficient without additional support.
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com